News
Public · Published
Evercore ISI Group maintains Hims & Hers Health at In-Line, raises price target to $27 from $24
Evercore ISI Group maintained its In-Line rating on Hims & Hers Health and raised its price target to $27 from $24, a 12.5% increase. The update changes the analyst's stated valuation target but leaves its rating unchanged.
Published:
Updated:
What happened
Evercore ISI Group maintained its In-Line rating on Hims & Hers Health and raised its price target to $27 from $24, a 12.5% increase. The update changes the analyst’s stated valuation target but leaves its rating unchanged.
Confirmed
Global impact / market context
The higher target signals that Evercore sees more potential value in Hims & Hers Health than before, while the unchanged In-Line rating shows it did not change its overall stance. The target itself does not change the company’s revenue, costs, or cash available.
Analyst inference
This is an analyst opinion update, not a report of new company results or a change in business plans. Investors may compare the higher target with the unchanged rating, but the supplied information gives no share price or explanation for Evercore’s revised valuation.
Analyst inference
What to watch
- Watch for any later change in Evercore’s rating or target; this update raised the target to $27 but kept the rating at In-Line. Analyst inference
- Look for company results or business updates that could clarify whether operating performance supports the higher target; none are provided in this article. Analyst inference
- Compare future analyst updates with this one to see whether other analysts also change their targets or ratings; the article reports only Evercore’s view. Analyst inference
Evidence
- Original source link unavailable